MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ — Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May […]
Recursion Pharmaceuticals raised $50 million from Nvidia via a PIPE that placed the AI biotech squarely into the investor fervor surrounding the tech company. Recursion said Wednesday morning it now plans to work with Nvidia […]
REC-3964 is designed to treat C. diff by selectively inhibiting the glucosyltransferase activity of toxin B produced by the bacterium in the gastrointestinal tract, offering a different mechanism of action from antibiotics. The post Recursion […]
Copyright © 2026 Biotech Networks
